MX2021005765A - Formulacion farmaceutica oral que contiene ibuprofeno. - Google Patents

Formulacion farmaceutica oral que contiene ibuprofeno.

Info

Publication number
MX2021005765A
MX2021005765A MX2021005765A MX2021005765A MX2021005765A MX 2021005765 A MX2021005765 A MX 2021005765A MX 2021005765 A MX2021005765 A MX 2021005765A MX 2021005765 A MX2021005765 A MX 2021005765A MX 2021005765 A MX2021005765 A MX 2021005765A
Authority
MX
Mexico
Prior art keywords
ibuprofen
oral pharmaceutical
pharmaceutical formulation
containing oral
component
Prior art date
Application number
MX2021005765A
Other languages
English (en)
Inventor
Yoichi Onuki
Satoru Yoshimura
Original Assignee
Ssp Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ssp Co Ltd filed Critical Ssp Co Ltd
Publication of MX2021005765A publication Critical patent/MX2021005765A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La provisión de tecnología para reducir el sabor desagradable del ibuprofeno en formulaciones farmacéuticas orales que contienen ibuprofeno; una formulación farmacéutica oral en la cual se reduce el sabor desagradable del ibuprofeno, que contiene (A) ibuprofeno o sal del mismo o solvato de estos, y (B) óxido de magnesio, en donde la relación entre masas [(B)/(A)] del componente (A) y del componente (B) es de 0.2 a 1.5.
MX2021005765A 2018-11-16 2019-11-15 Formulacion farmaceutica oral que contiene ibuprofeno. MX2021005765A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018215891 2018-11-16
PCT/JP2019/044835 WO2020101012A1 (en) 2018-11-16 2019-11-15 Ibuprofen-containing oral pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2021005765A true MX2021005765A (es) 2021-08-11

Family

ID=68733560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005765A MX2021005765A (es) 2018-11-16 2019-11-15 Formulacion farmaceutica oral que contiene ibuprofeno.

Country Status (11)

Country Link
US (1) US20210369618A1 (es)
EP (1) EP3880171B1 (es)
JP (1) JP7406349B2 (es)
KR (1) KR20210092202A (es)
CN (1) CN113038933A (es)
AU (1) AU2019380973A1 (es)
BR (1) BR112021009468A2 (es)
HU (1) HUE062682T2 (es)
MX (1) MX2021005765A (es)
PL (1) PL3880171T3 (es)
WO (1) WO2020101012A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230116831A (ko) * 2020-11-30 2023-08-04 에스에스 세야쿠 가부시키 가이샤 이부프로펜을 함유하는 고형 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
JP3159723B2 (ja) * 1991-03-22 2001-04-23 武田薬品工業株式会社 非晶質組成物およびその製造方法
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
JPH08337524A (ja) * 1995-06-15 1996-12-24 Taisho Pharmaceut Co Ltd イブプロフェン懸濁液剤
JP2001031562A (ja) 1999-07-16 2001-02-06 Taisho Pharmaceut Co Ltd 内服液剤
JP5296968B2 (ja) * 2005-06-17 2013-09-25 第一三共ヘルスケア株式会社 イブプロフェン含有経口用医薬組成物
CN101134013B (zh) * 2006-08-30 2012-07-18 Ss制药株式会社 口服用制剂
WO2010117035A1 (ja) * 2009-04-09 2010-10-14 ライオン株式会社 複合体及びその製造方法、ならびに粒状剤及び錠剤
CN103156812A (zh) * 2011-12-08 2013-06-19 杭州赛利药物研究所有限公司 右旋布洛芬干混悬剂及其制备方法
JP6580897B2 (ja) * 2015-08-24 2019-09-25 エスエス製薬株式会社 感冒用医薬組成物
JP6822034B2 (ja) * 2015-09-29 2021-01-27 大正製薬株式会社 安定性及び速効性の高いイブプロフェン含有固形製剤
JP6877923B2 (ja) * 2016-09-06 2021-05-26 ライオン株式会社 内服用半固形製剤及びその製造方法

Also Published As

Publication number Publication date
EP3880171A1 (en) 2021-09-22
WO2020101012A1 (en) 2020-05-22
PL3880171T3 (pl) 2024-02-19
EP3880171B1 (en) 2023-06-07
AU2019380973A1 (en) 2021-05-13
JP2020083884A (ja) 2020-06-04
KR20210092202A (ko) 2021-07-23
EP3880171C0 (en) 2023-06-07
US20210369618A1 (en) 2021-12-02
HUE062682T2 (hu) 2023-11-28
CN113038933A (zh) 2021-06-25
BR112021009468A2 (pt) 2021-08-10
JP7406349B2 (ja) 2023-12-27

Similar Documents

Publication Publication Date Title
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3811939A4 (en) PHARMACEUTICAL COMBINATION, COMPOSITION AND FORMULATION CONTAINING A GLUCOSIDASE ACTIVATOR AND A &X3B1;-GLUCOSIDASE INHIBITOR, METHODS OF PREPARING THEM AND USES THEREOF
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
EP3828183A4 (en) SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
EP3981399A4 (en) ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF
EP3876917A4 (en) LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD FOR MAKING IT
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
EP4252849A3 (en) Depot systems comprising glatiramer acetate
EP3849404A4 (en) SMALL HIGHLY UNIFORM NANOMEDICAL COMPOSITIONS FOR THERAPEUTIC, IMAGING AND THERANOSTIC APPLICATIONS
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
EP3760191A4 (en) PHARMACEUTICAL COMPOSITION, PROCESS FOR PREPARATION AND USE OF THE LATTER
EP4053152A4 (en) KERATIN BD-13, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4053154A4 (en) KERATIN BD-10, METHOD FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITION THEREOF, AND ITS USE
MX2021005765A (es) Formulacion farmaceutica oral que contiene ibuprofeno.
ZA202202319B (en) Oral pharmaceutical composition
SA521420957B1 (ar) FXIa تركيبة جديدة ثابتة عالية التركيز لأجسام مضادة تعمل ضد
WO2020194087A3 (en) Extended release pharmaceutical formulation
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
EP4234035A3 (en) A pharmaceutical combination for the treatment of a cancer
ZA202104617B (en) Pharmaceutical compound, the method of its making and use as medicinal agent
MX2022002356A (es) Forma de dosificacion oral solida que comprende naproxeno y vitamina b12.
EP4065598A4 (en) BIOTIN UNIT-CONJUGATED POLYPEPTIDES AND PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THEREOF